Tracking and tackling the tumor dynamics clonal evolution: osimertinib rechallenge after interval therapy might be an effective treatment approach in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC)

J Thorac Dis. 2022 Apr;14(4):816-819. doi: 10.21037/jtd-22-98.
No abstract available

Publication types

  • Editorial
  • Comment